Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myocet vs Doxorubicin in Neoadjuvant HER2+ Breast Cancer
NCT00712881Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Oct 2008
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of doxorubicin liposomal in breast cancer (2 arms), sponsored by Cephalon, Inc. Primary endpoint: Pathological Complete Response in Breast at Cycle 8. Started Oct 2008; status: completed.
02
Drugs
doxorubicin liposomal
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00712881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00712881.